Molecular biology · Bioinfo & AI
Whole-genome sequencing with AVITI and NovaSeq X Plus reveals comparable performance with contextual biases
Summary
This study benchmarks whole-genome sequencing (WGS) performance between Element AVITI and Illumina NovaSeq X Plus platforms using four human tumor cell lines. AVITI demonstrated lower duplication rates and higher base qualities, leading to improved mapping confidence and fewer spurious variant candidates. While both platforms were highly comparable for variant calling, AVITI offered a minor improvement for INDELs at lower coverages. Contextual differences were observed, with AVITI performing better in high-GC regions but worse in GC homopolymers, and showing sensitivity to G-quadruplex motifs. Overall, despite these specific differences, both platforms delivered highly comparable results for variant analysis.
Critical appraisal
This direct comparison of next-generation sequencing platforms is critical for genomics laboratories, especially those involved in oncology research and diagnostics. It provides detailed insights into the strengths and weaknesses of both AVITI and NovaSeq X Plus across various genomic contexts. Understanding these contextual biases and specific error profiles is essential for optimizing sequencing protocols, improving the accuracy of variant detection, and refining bioinformatics pipelines, thereby ensuring reliable results for both clinical and research applications.
The summary and the appraisal were written by a language model from the title and abstract of the original article. The article was selected automatically by a model, without human review. Methodology